The feasibility study of @entity3003 plus XXXX for advanced @entity151 with @entity16058 .

@entity1 @entity137 @entity16058 @entity5 @entity3003 @entity2 @entity2879 @entity2416 @entity151
BACKGROUND: @entity16058 ( @entity16058 ) are among the most common complications in @entity1 with @entity2 . In such @entity1 with @entity5 , the most serious expression of @entity137 in Japan is acute exacerbation of @entity16058 caused by anticancer treatment. Nevertheless, there has been no consensus and no evidence presented, regarding optimal treatment for advanced @entity2 with IIP. @entity1 AND METHODS: Chemotherapy-naive @entity1 with advanced @entity151 ( @entity151 ) with IIP who were ineligible for curative radiotherapy were enrolled. @entity1 received @entity3003 every 21 days at a dose of area under the curve 6.0 on day 1 and @entity2879 at a dose of 100 mg/m on days 1 to 3. RESULTS: Between July 2002 and October 2008, 17 @entity1 with @entity151 with IIP, including 14 @entity1 , eight of whom were diagnosed with @entity2416 , were enrolled and treated for a mean of 3.5 cycles of @entity3003 plus @entity2879 . One @entity1 (5.9%; 95% confidence interval, 0-18.4%) with clinically confirmed @entity2416 had acute exacerbation of @entity16058 associated with the treatment. The overall response rate was 88.2%. The median progression-free survival, median survival time, and 1-year survival rate were 5.5 months, 8.7 months, and 29.4%, respectively. CONCLUSION: This is the first report indicating that @entity1 with advanced @entity151 with @entity16058 may benefit from chemotherapy. @entity1 with advanced @entity151 with IIP treated with @entity2879 and @entity3003 combination chemotherapy gain benefits, with safety equivalent to that seen in @entity1 without IIP. The results from this study would support, on ethical grounds, the conduct of a large-scale study to evaluate this regimen.
